Merck KGaA, Darmstadt, Germany: Colorectal Neoplasms trials

The registry lists 19 Colorectal Neoplasms studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 6Phase 2 7Phase 3 3No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3
• Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)TerminatedNCT04515394Phase 2Results posted
• Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) GenotypeCompletedNCT01450319Phase 2Results posted
• A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type PatientsCompletedNCT01228734Phase 3Results posted
• MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)TerminatedNCT01085331Phase 1/2Results posted
• EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal CancerCompletedNCT01008475Phase 1/2Results posted
• Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study)CompletedNCT00778830Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.CompletedNCT00439517Phase 2Results posted
• Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)CompletedNCT00154102Phase 3Results posted
• Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)CompletedNCT00125034Phase 2Results posted
• Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsActive, not recruitingNCT06806046Phase 1
• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruitingNCT05464030Phase 1
• A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical PracticeCompletedNCT01460745
• An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal CancerTerminatedNCT01134666
• A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing TreatmentCompletedNCT01134640
• Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine PatientsCompletedNCT01082757
• A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing TreatmentCompletedNCT01082315
• An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing TreatmentTerminatedNCT01074333
• Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal CancerTerminatedNCT00719199Phase 1